Thyroid News

Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.

ChatGPT correctly answered more than two-thirds of submitted questions about thyroid nodules, though its responses may be at a grade level too high for patient education, according to study findings published in Thyroid.

More than 95% of adults with low-risk papillary thyroid cancer were disease-free after radiofrequency ablation, according to findings from a single-center study published in Thyroid.

Hemithyroidectomy is associated with better quality of life after surgery than total thyroidectomy for adults with low-risk differentiated thyroid cancer, though more studies are needed, according to findings from a systematic review.

Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.

Thyroid-stimulating hormone testing rates remained stable in the U.S. from 2006 to 2020, with about 10% of adults without thyroid disease receiving a test annually, according to study data.

Teprotumumab has marked the dawn of a new era in the treatment of thyroid eye disease.

Until recently, patients with active thyroid eye disease had limited options for treatment of their condition besides observation.

Exposure to a class of endocrine-disrupting chemicals may increase the risk for developing thyroid cancer, according to a study published in eBioMedicine.

Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.